<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04142931</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-19-6136-RS-CTIL</org_study_id>
    <nct_id>NCT04142931</nct_id>
  </id_info>
  <brief_title>Sequentional Immuno Apheresis Plasma Volume Escalation Cohort Study of Reduction of Soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) With or Without Nivolumab in Patients With Inoperable or Metastatic Solid Tumors</brief_title>
  <official_title>A Pilot Study, Single-Center, Open-Label, Sequentional Immuno Apheresis Plasma Volume Escalation Cohort Study of Reduction of Soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) With or Without Nivolumab in Patients With Inoperable or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Ronnie Shapira</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Immunicom Inc. San Diego California, USA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sequential immune apheresis plasma volume escalation cohort study of reduction of soluble&#xD;
      Tumor Necrosis Factors Receptors 1/2 (sTNFR1/2), with or without Nivolumab, in patients with&#xD;
      inoperable or metastatic solid Tumors. This study evaluates Immunicom fs LW-02 device used&#xD;
      with Spectra Optia apheresis system, aiming to answer two different study questions:&#xD;
&#xD;
        -  Safety, tolerability and effectiveness of the device.&#xD;
&#xD;
        -  Safety, tolerability and effectiveness of the device, employed as monotherapy, or&#xD;
           combined with Nivolumab.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a pilot, single-center, open-label, sequential immune apheresis plasma volume&#xD;
      escalation cohort study of reduction of soluble Tumor Necrosis Factors Receptors 1/2&#xD;
      (sTNFR1/2), with or without Nivolumab, in patients with inoperable or metastatic solid&#xD;
      Tumors. This study evaluates Immunicom fs LW-02 device used with Spectra Optia apheresis&#xD;
      system, aiming to answer two different study questions:&#xD;
&#xD;
        -  Safety, tolerability and effectiveness of the device.&#xD;
&#xD;
        -  Safety, tolerability and effectiveness of the device, employed as monotherapy, or&#xD;
           combined with Nivolumab.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 24, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events (Safety) of IA therapy with plasma volume escalation (increase from 2X to 3X plasma volume processed): adverse events</measure>
    <time_frame>two years</time_frame>
    <description>number of patients with adverse events that emerged due to IA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events (Safety and tolerability) of IA therapy in combination with nivolumab: adverse events</measure>
    <time_frame>two years</time_frame>
    <description>number of patients with adverse events that emerged due to IA therapy in combination with nivolumab.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Column efficiency</measure>
    <time_frame>two years</time_frame>
    <description>Changes in sTNFR-1/2 pre and post AIAC column between start and end of every treatment session, and between start and end of every cycle Total capture of sTNF-R1/2 on each column post treatment will be measured using an elution procedure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Column biochemical effectiveness</measure>
    <time_frame>two years</time_frame>
    <description>The biochemical efficacy will be evaluated throughout the study by measuring the changes of sTNFR-1/2 and TNFα in the plasma in several pre-defined time points - before, during and post every AIAC treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical efficacy: Response Rate (RR) as determined by RECIST v1.1</measure>
    <time_frame>two years</time_frame>
    <description>Response Rate (RR) as determined by RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating biomarkers in plasma cytokines Levels</measure>
    <time_frame>two years</time_frame>
    <description>changes in plasma cytokines levels: sTNFR-I (pg/ml), sTNFR-II (pg/ml), TNF (pg/ml), pre and post treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating biomarkers in peripheral blood mononuclear cells (PBMC)</measure>
    <time_frame>two years</time_frame>
    <description>changes in peripheral blood mononuclear cells (PBMC) phenotypes pre and post treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>two years</time_frame>
    <description>Duration of response (DoR) as determined by RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate</measure>
    <time_frame>two years</time_frame>
    <description>Clinical benefit rate (CBR) defined as CR plus PR plus stable disease (SD) ≥6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>two years</time_frame>
    <description>Progression-Free Survival (PFS) as determined by RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>two years</time_frame>
    <description>Overall Survival (OS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical efficacy by physician evaluation of ECOG status</measure>
    <time_frame>two years</time_frame>
    <description>Eastern Cooperative Oncology Group (ECOG) status (score 0-4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported outcomes by questionnaire EORTC QLQ-C30</measure>
    <time_frame>two years</time_frame>
    <description>Overall quality of life scale: 1 (very poor), 7 (excellent). higher score mean better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported outcomes by questionnaire EQ-5D- 5L</measure>
    <time_frame>two years</time_frame>
    <description>patient's health state: 1- 'The best health you can imagine' , 5- 'The worst health you can imagine'. higher score mean worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported outcomes by questionaire Hospital Anxiety and Depression Scale (HADS)</measure>
    <time_frame>two years</time_frame>
    <description>measure anxiety and depression in a general medical population of patients. 0-7 = Normal 8-10 = Borderline abnormal (borderline case) 11-21 = Abnormal (case)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Stage IV Non-small Cell Lung Cancer</condition>
  <condition>Stage IV Melanoma</condition>
  <condition>Triple Negative Breast Cancer</condition>
  <condition>Renal Cell Carcinoma Stage IV</condition>
  <arm_group>
    <arm_group_label>filtration of 2X PV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>filtration of 2X PV through the ImmunicomAIAC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>filtration of 2X PV combined with Nivolumab 240mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>filtration of 2X PV through the Immunicom AIAC, and nivolumab 240 mg given every 14 days for 4 times. Nivolumab will be initiated in C2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>ImmunicomAIAC</intervention_name>
    <description>filtration through the ImmunicomAIAC followed by Nivolumab Administrated IV starting C2.</description>
    <arm_group_label>filtration of 2X PV</arm_group_label>
    <arm_group_label>filtration of 2X PV combined with Nivolumab 240mg</arm_group_label>
    <other_name>Nivolumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ● Signed informed consent&#xD;
&#xD;
               -  Age ⩾ 18 years&#xD;
&#xD;
               -  Able to comply with study protocol, in the investigator's judgment&#xD;
&#xD;
               -  Histologically confirmed diagnosis of locally advanced unresectable, or&#xD;
                  metastatic (Stage IV) melanoma, triple negative breast cancer, non-small cell&#xD;
                  lung cancer, renal cell carcinoma&#xD;
&#xD;
               -  Progressed on at least one standard of care systemic therapy (e.g., chemotherapy&#xD;
                  or immunotherapy) in advanced/metastatic disease settings prior to inclusion in&#xD;
                  this study&#xD;
&#xD;
               -  Eastern Cooperative Oncology Group Performance Status of 0 or 1&#xD;
&#xD;
               -  Measurable disease according to RECIST v1.1&#xD;
&#xD;
               -  Life expectancy ⩾ 3 months&#xD;
&#xD;
               -  Adequate hematologic and end-organ function, defined by the following laboratory&#xD;
                  test results, obtained within 14 days prior to initiation of study treatment:&#xD;
&#xD;
                    -  ANC ≥ 1.5 x 109/L&#xD;
&#xD;
                    -  WBC ≥ 1.5 x 109/L&#xD;
&#xD;
                    -  Lymphocyte count ≥ 0.5 x 109/L&#xD;
&#xD;
                    -  Platelet count ≥ 100 x 109/L&#xD;
&#xD;
                    -  Hemoglobin ≥ 10g/dL (may be achieved with transfusion support)&#xD;
&#xD;
                    -  Serum albumin ≥ 3.2mg/dL&#xD;
&#xD;
                    -  Total bilirubin ≤ x1.5 ULN&#xD;
&#xD;
                    -  AST and ALT ≤ x2.5 ULN (in case of liver metastasis up to x5 ULN)&#xD;
&#xD;
                    -  ALP ≤ 2.5 x ULN (in case of liver or bone metastasis up to x5 ULN)&#xD;
&#xD;
                    -  Creatinine ≤x2 ULN&#xD;
&#xD;
                    -  Serum uric acid ≤ x1.5 ULN&#xD;
&#xD;
                    -  Calcium levels within normal range&#xD;
&#xD;
                    -  INR≤x1.5 ULN&#xD;
&#xD;
                    -  Adequate psychological and physical support structure&#xD;
&#xD;
               -  Female subjects may be enrolled in the trial if they are:&#xD;
&#xD;
                  ○ Of non-childbearing potential which is defined as: i. ⩾ 45 years of age and has&#xD;
                  not had menses for greater than 1 year ii. Amenorrhea for ⩾ 2 years without a&#xD;
                  hysterectomy and oophorectomy and FSH value in the postmenopausal range at&#xD;
                  screening evaluation iii. State post hysterectomy or oophorectomy or tubal&#xD;
                  ligation. 2. Of childbearing potential who have a negative pregnancy test result&#xD;
                  within 14 days prior to initiation of study, and agree to remain abstinent or use&#xD;
                  a contraceptive method with a failure rate of &lt;1% per year during the treatment&#xD;
                  period (bilateral tubal ligation, male sterilization, hormone releasing&#xD;
                  intrauterine device and copper intrauterine device; any hormonal contraceptive&#xD;
                  method must be supplemented with a barrier method)&#xD;
&#xD;
               -  Have provided tissue for biomarker analysis from a newly or recently-obtained&#xD;
                  biopsy (within 90 days of Study Day 1)&#xD;
&#xD;
               -  Willingness to undergo tumor biopsies of accessible lesions during treatment and&#xD;
                  at progression for exploratory biomarker analysis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ● Currently participating and receiving study therapy or has participated in a study&#xD;
             of an investigational agent and received study therapy or used an investigation device&#xD;
             within 2 weeks of treatment initiation&#xD;
&#xD;
               -  Has received prior chemotherapy, immunotherapy, radioactive or biological cancer&#xD;
                  therapy within 2 weeks prior to the treatment initiation, or who has not&#xD;
                  recovered to CTCAE Grade 1 or better from the clinically significant AEs due to&#xD;
                  cancer therapeutics administered more than 4 weeks prior to treatment initiation,&#xD;
                  except for stable neurosensory deficits related to chemotherapy and&#xD;
                  hypothyroidism or type I diabetes due to immunotherapy&#xD;
&#xD;
               -  Is expected to require any other form of systemic or localized antineoplastic&#xD;
                  therapy while in study&#xD;
&#xD;
               -  Known history of hematologic malignancy or of another primary solid tumor, unless&#xD;
                  the subject has undergone potentially curative therapy with no evidence of that&#xD;
                  disease for five years. The time requirement does not apply to the tumor for&#xD;
                  which the subject is enrolled in the study or subjects that underwent successful&#xD;
                  definitive resection of basal or squamous cell carcinoma of the skin, superficial&#xD;
                  bladder cancer, in situ cervical cancer, in situ breast cancer or other in situ&#xD;
                  cancers.&#xD;
&#xD;
               -  Have refused standard of care therapy CNS criteria&#xD;
&#xD;
               -  Actively progressing brain metastasis meaning new or enlarging known lesions.&#xD;
&#xD;
          -  Leptomeningeal metastasis&#xD;
&#xD;
          -  Intracranial hemorrhage in the last six months.&#xD;
&#xD;
          -  Patients with CNS metastasis will be eligible if:&#xD;
&#xD;
          -  All lesions treated with radiotherapy or surgery, and are stable for at least 4 weeks&#xD;
             prior to initiation of study treatment, and/or&#xD;
&#xD;
          -  Radiographically stable metastasis without local therapy over the last 3 months prior&#xD;
             to initiation of study treatment Cardiovascular criteria&#xD;
&#xD;
               -  Unstable angina or new-onset angina within 3 months prior to initiation of study&#xD;
&#xD;
               -  Symptomatic congestive heart failure defined as NYHA Class III or higher&#xD;
&#xD;
               -  Myocardial infarction within 6 months prior to initiation of study&#xD;
&#xD;
               -  Clinically significant hypotension, defined as systolic pressure under 90mmHg&#xD;
&#xD;
               -  Concurrent therapy with ACE inhibitors&#xD;
&#xD;
               -  Significant uncontrolled arrhythmias, with the exception of atrial fibrillation&#xD;
                  controlled for &gt;30 days prior to initiation of study treatment&#xD;
&#xD;
               -  EF&lt;55% Coagulation criteria&#xD;
&#xD;
               -  History of deep vein thrombosis or pulmonary embolism in the last 6 month.&#xD;
&#xD;
               -  Active or history of hypercoagulability/thrombophilia which is not related to the&#xD;
                  underlying condition.&#xD;
&#xD;
               -  Fibrinogen serum levels &gt;650mg/dL&#xD;
&#xD;
        Active infection criteria&#xD;
&#xD;
          -  Severe systemic infection within 4 weeks prior to initiation of study, including but&#xD;
             not limited to, hospitalization or complications of infection, bacteremia, fungemia,&#xD;
             infected stents or indwelling devices etc.&#xD;
&#xD;
          -  Signs and symptoms of infection within 2 weeks prior to initiation of study&#xD;
&#xD;
          -  Positive HIV test&#xD;
&#xD;
          -  Active Hepatitis B infection (chronic or acute), defined as a positive HbsAg test at&#xD;
             screening. Past or resolved HBV infection, defined as having a negative hepatitis B&#xD;
             surface antigen and a positive total hepatitis B core antibody at screening, are&#xD;
             eligible&#xD;
&#xD;
          -  Active Hepatitis C virus infection, defined as having a positive HCV antibody test and&#xD;
             a positive HCV RNA test at screening.&#xD;
&#xD;
          -  Treatment with a live attenuated vaccine within 4 weeks prior to initiation of study&#xD;
             Other criteria&#xD;
&#xD;
          -  Uncorrectable electrolyte abnormalities&#xD;
&#xD;
          -  Known hypersensitivity to apheresis&#xD;
&#xD;
          -  Current, severe, uncontrolled systemic illness other than cancer, that according to&#xD;
             the investigator's judgment should exclude the patient&#xD;
&#xD;
          -  Any psychological, familial, sociological or geographical condition that may mapper&#xD;
             compliance with the protocol and follow-up after treatment discontinuation&#xD;
&#xD;
          -  Pregnant or breastfeeding, or intending to become pregnant during the study&#xD;
&#xD;
          -  Known clinically significant liver disease, including alcoholism, cirrhosis or other&#xD;
             inherited liver diseases&#xD;
&#xD;
          -  Inability to install central line catheter&#xD;
&#xD;
          -  Treatment with anti TNF agents - infliximab (Remicade), adalimumab (Humira),&#xD;
             certolizumab pegol (Cimzia), and golimumab (Simponi), or etanercept (Enbrel).&#xD;
&#xD;
          -  Active autoimmune disease - known or suspected. Hypothyroidism or hypopituitarism&#xD;
             adequately treated with supplemental hormones, type 1 diabetes mellitus or skin&#xD;
             disorders (vitiligo, psoriasis, alopecia) not requiring systemic immunosuppression are&#xD;
             eligible.&#xD;
&#xD;
          -  Permanent systemic steroid therapy. Steroid treatment equal or less than 10 mg&#xD;
             prednisolone (or equivalent) is allowed.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ronnie Shapira, MD</last_name>
    <phone>972-3-5308414</phone>
    <email>ronnie.Shapira@sheba.health.gov.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Meital Bar</last_name>
    <phone>972-3-5305201</phone>
    <email>meital.bar@sheba.health.gov.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5262100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ronnie Shapira, Dr.</last_name>
      <email>ronnie.shapira@sheba.health.gov.il</email>
    </contact>
    <contact_backup>
      <last_name>Meital Bar</last_name>
      <phone>972-3-5305201</phone>
      <email>meital.bar@sheba.health.gov.il</email>
    </contact_backup>
    <investigator>
      <last_name>Ronnie Shapira, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>October 13, 2019</study_first_submitted>
  <study_first_submitted_qc>October 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2019</study_first_posted>
  <last_update_submitted>March 22, 2021</last_update_submitted>
  <last_update_submitted_qc>March 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sheba Medical Center</investigator_affiliation>
    <investigator_full_name>Dr. Ronnie Shapira</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
    <mesh_term>Necrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

